WASp signaling in T-cell lymphomas
- Institution
- UNIVERSITY OF ILLINOIS AT CHICAGO, IL
- Principal investigator
- Carlos A. Murga-Zamalloa
- Funding
- $472K
- Duration
- 2024–2029
Moonbase score
Still being scored
Abstract
ABSTRACT Title: WASp signaling in T-cell lymphomas Peripheral T-cell lymphomas (PTCL) are aggressive disorders, with less than 50% overall survival after 2-3 years of diagnosis. These dismal outcomes are in no small part secondary to the limited number of available biomarkers of disease progression and the limited knowledge of T-cell lymphoma biology. Emergent evidence indicates that the actin cytoskeleton plays a pivotal role during T-cell lymphomas' development and growth; however, actin-related proteins' role as actionable targets in T-cell lymphomas still needs to be defined. Our preliminary findings demonstrate that the actin regulatory protein Wiskott-Aldrich syndrome protein (WASp) is associated with decreased event-free survival and promotes T-cell lymphoma growth and survival. In this proposal, we will leverage a genetically engineered murine (GEM) model that develops spontaneous peripheral T-cell lymphomas (SNF5FL/CD4cre), and we will capitalize on an international consortium of more than 100 T-cell lymphoma cases collected with accompanying annotated clinical outcomes, to test the role of WASp during the assembly of actin-dependent signaling complexes upstream of oncogenic transcriptional signaling, and define the role of the tumor microenvironment driving WASp-dependent oncogenic signaling.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF ILLINOIS AT CHICAGO
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · University of Illinois at Chicago47
MASLD protection by STAT5-regulated transcription factors
Rhonda D Kineman · $825K · 2025–2030
- NIH · University of Illinois at Chicago47
Identifying a novel pathway that regulates RA immunometabolism
Shiva Shahrara · $715K · 2022–2028
- NIH · University of Illinois at Chicago45
Precise Combination Strategies Targeting Carbapenem-Resistant Klebsiella pneumoniae
Zackery P. Bulman · $720K · 2022–2027